Providence Swedish joins national study to help advance Long COVID research

Providence Swedish is enrolling patients in a national clinical trial that may help researchers better understand and treat Long COVID.
Long COVID happens when symptoms continue for months or even years after a COVID-19 infection. Symptoms can vary widely and may affect different parts of the body, including energy level, memory, concentration, breathing and heart function.
What the study is testing
The study, called REVERSE-LC, is funded by the National Institutes of Health. It is testing whether baricitinib, a medication already approved by the U.S. Food and Drug Administration for certain conditions, can help improve thinking and memory problems and reduce fatigue in people living with Long COVID.
Baricitinib works by calming parts of the immune system that can drive inflammation. Researchers want to learn whether this approach is safe and helpful for Long COVID symptoms.
“The REVERSE-LC trial is an exciting study that will move the field of Long COVID forward,” said Jason Goldman, M.D., an infectious disease specialist leading Providence Swedish’s participation in the trial. “We need to study baricitinib to help ensure it is safe and effective.”
Who can participate
People may qualify if they are 18 or older and have had thinking or memory problems for at least six months after a COVID infection.
Providence Swedish is one of 17 sites enrolling 550 adults nationwide and the only site in the Pacific Northwest participating in the trial. Participants are randomly assigned to receive either baricitinib or a placebo, which helps researchers compare results fairly.
The trial was designed with input from the Patient-Led Research Collaborative, a Long COVID advocacy group made up of people with lived experience. The group gave the study a strong score for reflecting patient priorities and involving patient-researchers in the design process.
If you would like to learn more or consider participating in REVERSE-LC, you can sign-up for the Swedish Long COVID Registry or email us at RDResearch@swedish.org.
Why clinical trials matter
Clinical trials help researchers learn what treatments work, who they help and how safe they are. For people living with Long COVID, participation can also be a way to contribute to answers that may benefit others.
Amy Rosas, a 53-year-old mother of two from Kirkland, has participated in three Long COVID trials through Providence Swedish. She said Long COVID affected her physical and mental health, her ability to work and her ability to be active with her family.
“Participation in each clinical trial has cumulatively helped improve my physical and mental health,” Rosas said. “Taking part helps provide personal and collective benefit for everyone affected by this debilitating condition.”
About Providence Swedish
Providence Swedish has served the Puget Sound region since the first Providence hospital opened in Seattle in 1877 and the first Swedish hospital opened in 1910. The two organizations affiliated in 2012 and today comprise the largest health care delivery system in Western Washington, with 24,000 caregivers, eight hospitals and 244 clinics throughout Western Washington – from Everett to Centralia. A not-for-profit family of organizations, Providence Swedish provides more than $545 million in community benefit in the Puget Sound region each year. The health system offers a comprehensive range of services and specialty and subspecialty care in a number of clinical areas, including cancer, cardiovascular health, neurosciences, orthopedics, digestive health and women’s and children’s care. For more information, visit providence.org/swedish.